Trial Profile

MinPAC: A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Minnelide (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms MinPAC

Most Recent Events

10 Apr 2024 Results (n=17) assessing clinical anticancer effects, and to define effects of the drug on super enhancer expression and downstream effects presented at the 115th Annual Meeting of the American Association for Cancer Research
01 Sep 2020 Status changed from active, no longer recruiting to completed.
24 Apr 2020 Planned End Date changed from 31 Mar 2020 to 31 May 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com